Personalis Real-Time Variant Tracker identifies resistance mutations across several hundred clinically relevant hotspots

City of Hope to evaluate Quest Diagnostics’ Haystack MRD for guiding patient management in multiple cancers

Quest Diagnostics, a provider of diagnostic information services, announced that City of Hope is implementing Haystack MRD, a circulating-tumor DNA minimal residual disease test, for clinical trial participants with solid tumor cancers to help guide disease management for patients being treated for breast, colorectal, ovarian, and prostate cancer.

April 24, 2026

Vol.52 No.16

Cancer Policy

FDA adds stereotactic breast biopsy needles to the shortage list

FDA has added stereotactic breast biopsy needles to its Medical Device Shortages List with an estimated duration of “through Q4 2026,” which spans July 1 to Sept. 30.

Sheila Efron Taube honored by Brandeis with Alumni Achievement Award

Brandeis University has announced that Sheila Efron Taube ’63, a pioneer in cancer research, will receive the Alumni Achievement Award for outstanding contributions to their fields and society.

April 17, 2026

Vol.52 No.15

Clinical Roundup

Clinical trial aims to address vaginal complaints after breast cancer diagnosis

The Alliance for Clinical Trials in Oncology is enrolling patients into a clinical trial aimed at helping women recover from the vaginal side effects of breast cancer treatment.

April 17, 2026

Vol.52 No.15

Guest Editorial

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers

In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies.

April 03, 2026

Vol.52 No.13

By Nicholas Richardson

Drugs & Targets

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

FDA has approved Ponlimsi (denosumab-adet) as a biosimilar to Prolia.

April 03, 2026

Vol.52 No.13

Personalis Real-Time Variant Tracker identifies resistance mutations across several hundred clinically relevant hotspots

YOU MAY BE INTERESTED IN

City of Hope to evaluate Quest Diagnostics’ Haystack MRD for guiding patient management in multiple cancers

FDA adds stereotactic breast biopsy needles to the shortage list

Sheila Efron Taube honored by Brandeis with Alumni Achievement Award

Clinical trial aims to address vaginal complaints after breast cancer diagnosis

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

Renew today!

Subscriber content

Never miss an issue!

Login

Personalis Real-Time Variant Tracker identifies resistance mutations across several hundred clinically relevant hotspots

YOU MAY BE INTERESTED IN

City of Hope to evaluate Quest Diagnostics’ Haystack MRD for guiding patient management in multiple cancers

FDA adds stereotactic breast biopsy needles to the shortage list

Sheila Efron Taube honored by Brandeis with Alumni Achievement Award

Clinical trial aims to address vaginal complaints after breast cancer diagnosis

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters mostDraft guidance consolidates trial design updates for developers

FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients

Never miss an issue!

Login

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers